Therapeutic Innovation : Discovery Across Boundaries
U1177 (formerly U761), directed by Pr. Benoit Deprez, is dedicated to drug design, discovery and selection.
The Lab's mission is to design and study compounds that modulates selected molecular targets in a desired way to treat infectious and metabolic diseases.
Our projects engage researchers across physical, chemical and biological sciences to trade ideas and knowledge and sincerely endeavor to validate new therapeutic concepts with drug prototypes and bring drugs candidates to the clinic.
- Developing cutting edge methods for quantitative pharmacology (High Content Screening, Pharmacokinetics)
- Designing the next generation of anti-TB antibiotics : ethionamide boosters.
- Deciphering the role(s) of Insulin Degrading Enzyme in diabetes with several families of modulators.
- Modulating the molecular interplay between intestine, liver and muscles with TGR5 ligands to treat diabetes.
- Developing small chemical modulators of antigenic presentation.
We are open to any type of collaboration with biologists or chemist from academia and industry where medicinal chemistry, in vitro pharmacology and pharmacokinetics enable or accelerate the translation of new therapeutic concept into drug discovery.
Our researchers are committed to the highest standards of scientific quality and integrity in everything they do. We use up-to date electronic lab books to sustainably capitalize knowledge and facilitate collaborations between multiple research sites.
Most of our researchers are also faculty members who teach in PharmD and MSc courses in pharmacy, drug discovery, medicinal chemistry, organic chemistry, and R&D strategies.
A journey with the team
Reversion of antibiotic resistance by SMARt-420
Read U1177 and U1019 paper in Science:
Blondiaux, N., et al. Reversion of antibiotic resistance in M. tuberculosis by SMARt-420. Science,2017, 355(6330): 1206-1211. doi:10.1126/science.aag1006
- Science Mag : Biological version of malware reverses antibiotic resistance in TB
- Nat. Chem. Biol :Out-SMARting drug resistance
- Nat. Rev. Drug Disc. : Reversing resistance
- NEJM : Reviving a Drug for Tuberculosis?
- Le Monde : Tuberculose multirésistante : un vieil antibiotique ressuscité
- C&EN : Reversing resistance to a tuberculosis antibiotic
Machelart, A., et al. β-Cyclodextrins Nanoparticles as Drug Nanocarriers against Tuberculosis. ACS Nano,2019 link
Tanina, A., et al protein-ligand interactions in EthR. BBA 2019, 1867(3): 248-258. link
Colin, B., et al High-throughput DNA plasmid transfection using acoustic droplet ejection technology. SLAS Discovery,2018: in press. link
Prieri, M. et al. Analogs of ethionamide Eur. J. Med. Chem.,2018, 159: 35-46.link
Zhang, Z. et al. Ensemble cryoEM ofIDE. eLife,2018, 7: e33572. link
Hoguet, V., Supercritical fluid chromatography for dihydropyridones. J. Chromatogr. A,2018, 1549: 39-50.link
Kussau, T., et al. Structural rearrangementsof MabA. Acta crystallographica. Section D, Structural biology,2018, 74(Pt 5): 383-393. link
Hering, Y., REV-ERBα cell-based assay. 2018,2018. link
Montaigne, D., et al Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: . Lancet,2018, 391(10115): 59–69 link